FDA Approves TAUKLARIFY, a New Tau PET Imaging Agent for Alzheimer's Disease Diagnosis

The U.S. Food and Drug Administration (FDA) has approved TAUKLARIFY (florquinitau F 18 injection), a tau PET imaging agent, for identifying tau neurofibrillary tangle pathology in adults being evaluated for Alzheimer's disease. This diagnostic tool is expected to improve the understanding of Alzheimer's disease status across the spectrum of cognitive impairment, including early stages.